Institution
Stormont Vail Health
Healthcare•Topeka, Kansas, United States•
About: Stormont Vail Health is a healthcare organization based out in Topeka, Kansas, United States. It is known for research contribution in the topics: Pregnancy & Medicine. The organization has 22 authors who have published 27 publications receiving 154 citations.
Topics: Pregnancy, Medicine, Prospective cohort study, Ferritin, Population
Papers
More filters
••
University of Missouri–Kansas City1, Mayo Clinic2, Wake Forest University3, Northwestern University4, Emory University5, Cardiovascular Institute of the South6, Johns Hopkins University School of Medicine7, NorthShore University HealthSystem8, University of Utah9, University of Maryland, Baltimore10, Stormont Vail Health11, Allegheny Health Network12, Eastern Virginia Medical School13, Harvard University14, University of Southern California15
TL;DR: In this paper, the authors evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of KCCQ-CS, a measure of heart failure-related health status, at 12 weeks after treatment initiation.
Abstract: Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3–9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0–9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7–10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6–34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1–7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05–2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01–1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking.
217 citations
••
Discovery Institute1, Katholieke Universiteit Leuven2, Lund University3, Mayo Clinic4, University of Washington5, Children's Hospital of Orange County6, University of California, Irvine7, Başkent University8, Medical University of Białystok9, University of Catania10, Harvard University11, Boston Children's Hospital12, Washington University in St. Louis13, University of Pennsylvania14, National Institutes of Health15, University of Newcastle16, Children's Hospital of Philadelphia17, Stormont Vail Health18, Odense University Hospital19, Royal Children's Hospital20, University of Southampton21, University of Kentucky22, University of Alabama at Birmingham23, Carolinas Healthcare System24, University of South Florida25, University of California, Los Angeles26, Icahn School of Medicine at Mount Sinai27
TL;DR: The number of known patients and previously unreported cases of ALG1‐CDG are identified and characterized, and the recently identified protein‐linked xeno‐tetrasaccharide biomarker, NeuAc‐Gal‐GlcNAc2, was seen in all 27 patients tested.
Abstract: Congenital disorders of glycosylation (CDG) arise from pathogenic mutations in over one hundred genes leading to impaired protein or lipid glycosylation. ALG1 encodes a β1,4 mannosyltransferase that catalyzes the addition of the first of nine mannose moieties to form a dolichol-lipid linked oligosaccharide intermediate (DLO) required for proper N-linked glycosylation. ALG1 mutations cause a rare autosomal recessive disorder termed ALG1-CDG. To date thirteen mutations in eighteen patients from fourteen families have been described with varying degrees of clinical severity. We identified and characterized thirty-nine previously unreported cases of ALG1-CDG from thirty-two families and add twenty-six new mutations. Pathogenicity of each mutation was confirmed based on its inability to rescue impaired growth or hypoglycosylation of a standard biomarker in an alg1-deficient yeast strain. Using this approach we could not establish a rank order comparison of biomarker glycosylation and patient phenotype, but we identified mutations with a lethal outcome in the first two years of life. The recently identified protein-linked xeno-tetrasaccharide biomarker, NeuAc-Gal-GlcNAc2, was seen in all twenty-seven patients tested. Our study triples the number of known patients and expands the molecular and clinical correlates of this disorder.
35 citations
••
TL;DR: Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
Abstract: Background. Children under 3 years of age may benefit from a double-dose of inactivated quadrivalent influenza vaccine (IIV4) instead of the standard-dose. Methods. We compared the only United States-licensed standard-dose IIV4 (0.25 mL, 7.5 µg hemagglutinin per influenza strain) versus double-dose IIV4 manufactured by a different process (0.5 mL, 15 µg per strain) in a phase III, randomized, observer-blind trial in children 6-35 months of age (NCT02242643). The primary objective was to demonstrate immunogenic noninferiority of the double-dose for all vaccine strains 28 days after last vaccination. Immunogenic superiority of the double-dose was evaluated post hoc. Immunogenicity was assessed in the per-protocol cohort (N = 2041), and safety was assessed in the intent-to-treat cohort (N = 2424). Results. Immunogenic noninferiority of double-dose versus standard-dose IIV4 was demonstrated in terms of geometric mean titer (GMT) ratio and seroconversion rate difference. Superior immunogenicity against both vaccine B strains was observed with double-dose IIV4 in children 6-17 months of age (GMT ratio = 1.89, 95% confidence interval [CI] = 1.64-2.17, B/Yamagata; GMT ratio = 2.13, 95% CI = 1.82-2.50, B/Victoria) and in unprimed children of any age (GMT ratio = 1.85, 95% CI = 1.59-2.13, B/Yamagata; GMT ratio = 2.04, 95% CI = 1.79-2.33, B/Victoria). Safety and reactogenicity, including fever, were similar despite the higher antigen content and volume of the double-dose IIV4. There were no attributable serious adverse events. Conclusions. Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
24 citations
••
University of North Carolina at Chapel Hill1, Pennington Biomedical Research Center2, Dartmouth College3, Stormont Vail Health4, University of California, Davis5, Cornell University6, George Washington University7, University of Maryland, Baltimore8, University of Pennsylvania9, University of Vermont10, Albert Einstein Medical Center11, Rowan University12, Medical College of Wisconsin13
TL;DR: A systematic review of the literature of purported dietary supplements and alternative therapies for weight loss is presented in this article, where the authors evaluated the efficacy of 14 dietary supplements, therapies, or a combination thereof.
Abstract: Objective Dietary supplements and alternative therapies are commercialized as a panacea for obesity/weight gain as a result of the minimal regulatory requirements in demonstrating efficacy. These products may indirectly undermine the value of guideline-driven obesity treatments. Included in this study is a systematic review of the literature of purported dietary supplements and alternative therapies for weight loss. Methods A systematic review was conducted to evaluate the efficacy of dietary supplements and alternative therapies for weight loss in participants aged ≥18 years. Searches of Medline (PubMed), Cochrane Library, Web of Science, CINAHL, and Embase (Ovid) were conducted. Risk of bias and results were summarized qualitatively. Results Of the 20,504 citations retrieved in the database search, 1,743 full-text articles were reviewed, 315 of which were randomized controlled trials evaluating the efficacy of 14 purported dietary supplements, therapies, or a combination thereof. Risk of bias and sufficiency of data varied widely. Few studies (n = 52 [16.5%]) were classified as low risk and sufficient to support efficacy. Of these, only 16 (31%) noted significant pre/post intergroup differences in weight (range: 0.3-4.93 kg). Conclusions Dietary supplements and alternative therapies for weight loss have a limited high-quality evidence base of efficacy. Practitioners and patients should be aware of the scientific evidence of claims before recommending use.
19 citations
••
TL;DR: In a statewide study of nurse educators from nationally accredited ADN programs, 42 of 109 baccalaureate outcomes were reported met in their programs and those outcomes clustered in 3 areas: information management and application of technology, professionalism and professional values, and generalist nursing practice.
Abstract: In a statewide study of nurse educators from nationally accredited ADN programs, 42 of 109 baccalaureate outcomes were reported met in their programs Those outcomes clustered in 3 areas: information management and application of technology, professionalism and professional values, and generalist nursing practice The 67 outcomes that were not met were in the categories of liberal education, organizational and systems leadership, evidence-based practice, healthcare policy, finance and regulatory environments, interprofessional collaboration, and population health This research provides important evidence from which to construct an outcomes-based associate degree to baccalaureate curriculum
19 citations
Authors
Showing all 24 results
Name | H-index | Papers | Citations |
---|---|---|---|
Chris Moody | 3 | 3 | 28 |
Vijay S. Are | 3 | 4 | 17 |
Shamik Shah | 3 | 13 | 36 |
Jakica Tancabelic | 2 | 3 | 19 |
Rachel Mellenbruch | 1 | 1 | 9 |
Theresa M. Tetuan | 1 | 1 | 11 |
Bradley K. Woods | 1 | 1 | 5 |
Jo Ann S. Harris | 1 | 1 | 24 |
Katarina Gambosova | 1 | 1 | 2 |
Shelly McMaster | 1 | 1 | 13 |
Chen H Chow | 1 | 1 | 3 |
Fatma A Radhi | 1 | 1 | 1 |
Tahernia Ac | 1 | 1 | 3 |
Lenora Kinzie | 1 | 1 | 13 |
Patria Alba | 1 | 2 | 4 |